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Abstract
Background: Dendritic cells (DCs) are major orchestrators of immune responses and inflammation. They are
migratory cells, which may play a role in Alzheimer’s disease (AD), as suggested by prior in vitro studies. With the
intent to investigate the clinical relevance of DC modifications in vivo, the present study was aimed to evaluate the
levels of blood DCs in AD patients, in relation to the progression of the disease, the severity of its symptoms, and
the treatment with acetylcholinesterase inhibitors (AChEIs), a class of drugs used to improve cognitive
functioning in people with dementia.
Methods: The two main subpopulations of immature blood DCs, namely myeloid (mDCs) and plasmacytoid
(pDCs) cells, were evaluated by flow cytometry analysis in 106 AD patients, in comparison with the same cells
from 65 individuals with mild cognitive impairment (MCI) and 73 healthy control subjects (HC). The relationship
between blood DC levels and symptom severity was also assessed in AD patients, and their blood DC frequency
was considered both in the absence or presence of treatment with AChEIs.
Results: A significant depletion in blood mDCs was observed in AD patients, as compared to HC and MCI
subjects. At variance, pDC levels were comparable among the three groups of subjects. The mDC decrease
was evident only after the emergence of AD clinical symptoms, as confirmed by the follow-up analysis of a
subgroup of MCI subjects who exhibited a significant decline in mDCs after their conversion to AD. Notably,
the mDC decline was inversely correlated in AD patients with the frequency and severity of depressive
symptoms. Eventually, the mDC depletion was not observable in patients treated with AChEIs.
Conclusions: Our results provide the first evidence that blood mDC levels are dysregulated in AD. This
phenomenon appears mainly linked to AD progression, associated with stronger severity of AD-related
symptoms, and influenced by AChEI treatment. Taken all together, these data suggest that blood mDCs
may serve as a cell source to test disease-induced and treatment-related changes and support the innovative
notion that DCs play a role in AD, as ultimate evidence of the immune system participation in disease progression.
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Background
In association with amyloid plaques, reactive microglia
have been broadly observed in AD brain. These cells are
considered the resident mononuclear phagocytes, which
act as the first line of brain defense, like macrophages in
the periphery, and are associated with the release of
many inflammatory factors in AD brains, such as com-
plement factors, pro-inflammatory cytokines and che-
mokines [1]. Similarly, pro-inflammatory mediators
(mainly cytokines and chemokines) are also increased
outside the CNS of AD patients and in particular in
their peripheral blood [2]. Peripheral immune changes
seem to occur in AD patients also at cellular level, espe-
cially regarding the myelomonocytic cells. Even though
blood monocyte percentage appears similar in AD and
controls [3], in vitro-stimulated AD monocytes acquire a
pro-inflammatory phenotype with secretion of higher
levels of IL-6 [4]. Moreover, monocytes obtained from
AD patients have a limited potential to differentiate into
macrophages, which, in turn, show an impaired phago-
cytosis of amyloid β (Aβ) [5].
Following brain damage, an innate immune response
takes place, mainly consisting of resident microglia and
peripherally derived monocytes, macrophages [6], and,
possibly, dendritic cells (DCs) [7]. Thus, it is not surpris-
ing that emerging data point to blood-derived mono-
nuclear phagocytes as potential players in AD, as shown
in mouse models [8–11]. DCs are the most potent pro-
fessional antigen-presenting cells that play a central role
in the initiation and modulation of innate and adaptive
immune response [12], but their role in AD context is
still largely unexplored. DCs may play an important role
in brain diseases as they can reach CNS from periphery
in both human diseases [13] and animal models [14]
including AD [7]. Unfortunately, the characterization of
DCs in human CNS is hard because of their relative
paucity in the brain parenchyma, the in vivo analysis is
difficult to perform, and the phenotypic characterization
is complex, due to the absence of specific markers that
are able to clearly distinguish DCs from microglia. Not-
ably, before entering tissues and exerting their specific
biological activity, immature DCs may circulate in the
blood, so their analysis in the periphery would provide
insights to better understand their involvement in brain
diseases. More specifically, blood DCs represent less
than 1 % of circulating mononuclear cells (PBMCs) in
the peripheral blood, where they act as “immunological
sentinels”. Two major subsets of human blood DCs,
myeloid and plasmacytoid DCs (mDCs and pDCs, re-
spectively), have been classified [15, 16]. Overall, both
subsets of circulating DCs function as sentinels, which
rapidly mature in response to antigenic stimulation, mi-
grate to tissues, secrete cytokines, and effectively stimu-
late T cells. At variance with the pDC subset, mDCs are
specifically considered precursor other than immature
cells, since they fail to mature in response to TNF-α and
express high levels of early myeloid markers, including
CD33 [16]. Though the functional role of blood DCs
and their subsets still needs to be clarified, a modifica-
tion of their steady state has been often reported in age-
ing [17, 18] and in several pathological conditions,
including CNS diseases and neurodegeneration [19–21],
though not yet in AD. The knowledge about a potential
involvement of DCs in AD is limited and mainly
derived from in vitro data. We previously described
that monocyte-derived DCs from AD patients show a
more pronounced proinflammatory profile than DCs
obtained from healthy control (HC) subjects [3]. This
phenomenon could be associated to altered metabolism
of Aβ, since monocyte-derived DCs obtained from HC
and generated in vitro with Aβ1–42 peptide show func-
tional alteration and increased production of inflamma-
tory molecules [22]. In addition, we reported that
monocyte-derived DCs from AD patients have a re-
duced ability to produce brain-derived neurotrophic
factor following stimulation with Aβ1–42 peptide [23],
providing evidence in support of the concept that mye-
loid DCs might participate in AD brain damage by pro-
moting both inflammatory response and Aβ-dependent
neurotoxic pathways.
Given the migratory nature of DCs and their potential
recruitment to brain during neurodegeneration, the
present study was addressed to confirm the possible par-
ticipation of DCs in AD by evaluating the levels of the
two DC subsets present in the blood of AD patients, in
comparison with HC subjects. Then, in order to assess
when blood DC changes occur during the progression of
dementia, the blood DC analysis was performed also in
a group of individuals with primary memory impair-
ments, namely amnestic mild cognitive impairment
(MCI), who are considered at increased risk to develop
AD [24], as well as in a subgroup of MCI who converted
to AD. With the intent to identify possible relationships
between levels of blood DCs and clinical characteris-
tics, the frequency of DC subpopulations in the blood
was correlated with symptom severity in AD patients.
Eventually, the impact on blood DC levels of acetyl-
cholinesterase inhibitors (AChEIs), the drugs used as




This study focused on 244 subjects consecutively re-
cruited in the outpatient memory clinic of Santa Lucia
Foundation in Rome, Italy. Among those, 106 patients
were diagnosed with “probable AD”, 65 subjects with
amnestic MCI, and 73 persons were included as HC.
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Medical and psychiatric history were obtained from each
subject, and all patients underwent a series of standard
clinical evaluations, including physical, neurological, and
mental status examinations and brain magnetic reson-
ance imaging. The study was approved by the Santa
Lucia Foundation Ethical Committee, and, in accordance
with the Helsinki Declaration, written informed consent
was obtained from patients, patient representatives, or
caregivers prior to enrollment.
Common exclusion criteria applied to all subjects
were (i) major medical illness (e.g., cancer, obstructive
pulmonary disease or asthma, hematologic disorders,
active gastrointestinal, renal, hepatic, endocrine, car-
diovascular diseases) and autoimmune inflammatory
disorders (e.g., rheumatoid arthritis, type I diabetes, psor-
iasis, systemic lupus erythematosus, overt infections); (ii)
comorbidity of primary psychiatric (i.e., schizophrenia,
major depression onset before the AD onset) or neuro-
logical disorders (i.e., stroke, Parkinson’s disease (PD),
seizure disorder, or head injury with loss of consciousness
within the past year); (iii) known or suspected history of
alcoholism or drug abuse; and (iv) computed tomography
or magnetic resonance imaging evidence of focal paren-
chymal abnormalities.
Inclusion criteria for AD patients were (i) diagnostic
evidence of probable AD consistent with the NINCDS-
ADRDA criteria [25]; (ii) mild to moderate severity of
dementia, defined as mini-mental state examination
(MMSE) score ranging from 26 to 10 [26]; (iii) vision
and hearing sufficient for compliance with testing proce-
dures; and (iv) laboratory values within normal limits or
considered not clinically relevant by the investigator.
Specific inclusion criteria for MCI were (i) diagnostic
evidence of amnestic MCI consistent with Petersen
guidelines [27]; (ii) a MMSE score ≥23. MCI patients
were at the onset of their cognitive impairment and
underwent their first clinical examination for the diagno-
sis of MCI. To better establish whether blood DC modi-
fications are specific of AD and when they occur during
disease progression, MCI patients were followed for two
consecutive years at 6-month clinical follow-up visits
aimed at verifying conversion to AD or to confirm the
MCI condition. A subgroup of 11 MCI patients (16.9 %
of the MCI cohort) who progressed over a 2-year time
period to AD was eventually identified within the main
group, indicated as MCI converters. They had blood
drawn and DC analysis both at MCI baseline condition
and at conversion.
The HC were neither related to one another nor to
AD patients. Their inclusion criteria were (i) vision and
hearing sufficient for compliance with testing proce-
dures; (ii) laboratory values within the appropriate
normal reference intervals; and (iii) neuropsychological
domain scores above the cutoff scores, corrected for age
and educational level, identifying normal cognitive level
in the Italian population. Specific exclusion criteria for
HC subjects were (i) dementia diagnosis, according with
DSM-IV criteria or MCI according with Petersen cri-
teria, and confirmed by the administration of the MDB
and (ii) MMSE score <26 according with standardized
norms for the Italian population [28].
Demographic, cognitive, and neuropsychiatric assessment
Information on age, education, and sex was collected at
baseline and verified by the patient’s informant. Global
cognitive functioning was assessed with the MMSE [26], a
commonly used neurocognitive screening test addressed to
make the first dementia diagnosis and to assess its progres-
sion and severity. MMSE measures orientation, language,
verbal memory, attention, visuospatial function, and mental
control, with scores ranging from 30 (no impairment) to 0
(maximum impairment).
To evaluate the severity of participants’ neuropsychi-
atric symptoms, we administered to each participant the
neuropsychiatric inventory (NPI) [29]. If appropriate, a
family caregiver completed the NPI for the participant.
The NPI was used to assess the frequency and severity
of neuropsychiatric symptoms in 12 domains: delu-
sions, hallucinations, agitation, depression, anxiety, eu-
phoria, apathy, disinhibition, irritability, aberrant motor
behavior, nighttime behavior disturbances, appetite, and
eating abnormalities. Frequency was rated from 1 (oc-
casionally) to 4 (very frequently) and severity from 1
(mild) to 3 (severe). If the symptom was absent, a score
equal to 0 was given. The multiplication of frequency
and severity was used as symptom composite score,
with a range from 0 to 12.
To assess the patients’ ability to perform the activities
of daily living independently, basic activities of daily
living (ADL) were assessed using the Katz scale [30]. In-
strumental ADL was assessed with Lawton and Brody’s
I-ADL scale [31]. The ADL and the I-ADL scales range
from severe functional impairment (higher scores) to
fully functioning (lower scores). They were treated as
continuous variables.
Among the 106 AD patients included in the study, 66
(62.3 %) were treated at baseline with the AChEI drug
rivastigmine whereas 40 (37.7 %) were free from any
AChEI treatment. Considering that taking AChEI may
be a confounding factor for circulating immune cell
analyses because of possible anti-inflammatory activity
of these drugs, we split the AD group in the two sub-
groups of untreated (AD w/o AChEI) and AChEI-
treated patients.
Furthermore, at the moment of the clinical assessment
and blood sampling collection, the following fraction of
group subjects were depressed and treated with antide-
pressants: 12.3 % of MCI and 10.3 % of AD patients. In
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particular, blood donors utilized the following antide-
pressants: paroxetine (1/65), sertraline (3/65), citalopram
(1/65), and escitalopram (3/65) in MCI and paroxetine
(1/106), sertraline (3/106), citalopram (1/106), and esci-
talopram (6/106) in AD.
Baseline characteristics of the HC, MCI, and AD sub-
jects used in this study, including AD subgroups, were
reported in Table 1. MCI subgroups, converters and no-
converters, were described in Table 2. All groups were
age and gender balanced according to chi-square test
analysis (data not shown).
Blood samples and flow cytometry analysis
Peripheral blood samples were obtained by venipuncture,
collected into 10-ml tubes (EDTA Vacutainer, BD Biosci-
ences, San Diego, CA, USA), processed, and stained
within 4 h of collection. The blood draws were done in
the morning to avoid the influence of circadian rhythm on
levels of circulating immune cells. The frequency of per-
ipheral blood DCs was assessed by flow cytometry analysis
according to the manufacturer’s instructions and as
described elsewhere [21]. In brief, 200 μL of whole blood
were incubated for 20 min at room temperature with anti-
lin-1 FITC (i.e., CD3, CD14, CD16, CD19, CD20, and
CD56), anti-HLA-DR PerCP, anti-CD11c APC, anti-
CD123 PE, and their isotype-matched monoclonal anti-
bodies (all from Becton Dickinson, San Jose, CA, USA).
Stained blood samples were subjected to erythrocytes lysis
with 2 mL of FACS lysing solution (Becton Dickinson),
vortexed and incubated for 10 min at RT in the dark. Fol-
lowing washing, samples were stored at +4 °C in the dark
and analyzed within 1 h. Fifty thousand events were ac-
quired with a four-color FACScalibur flow cytometer (BD
Biosciences) running CellQuest software (BD Biosciences).
Blood DCs were defined as lin-1−/HLA-DR++ cells. Blood
DC subsets were identified using CD11c (mDCs) or
CD123 (pDCs) antibodies. Representative panels that de-
scribe the gating strategy are reported in Fig. 1.
Statistical analysis
Data are shown in dot plots and expressed as mean
values ± SE. All statistical analyses were performed using
Prism 4 software (GraphPad Software Inc). Comparisons
between groups were made using the non-parametric
two-tailed Mann-Whitney test for unpaired data or a
two-tailed Wilcoxon signed rank test for paired data, as
appropriate. Correlation analyses were made using
Spearman’s rank test. Results were considered to be sta-
tistically significant when p value was < 0.05.
Results
mDC percentage is decreased in peripheral blood from
AD patients as compared to MCI and HC subjects
We firstly investigated by flow cytometry the relative
proportion of peripheral blood DC subsets, more specif-
ically mDCs and pDCs, in the three main groups of
subjects, namely HC, MCI, and AD. The clinical charac-
teristics of the three groups of subjects are summarized
in Table 1. As reported in Fig. 2a, the mean percentage
of mDCs was significantly decreased in AD patients
(0.20 ± 0.009), as compared to HC (0.24 ± 0.012, p =
0.01) or MCI (0.26 ± 0.011, p < 0.0001), while no statisti-
cally significant differences were observed between HC
and MCI subjects. There were no differences in levels of
pDCs among AD, MCI, and HC (Fig. 2b).
Blood mDC reduction is observed after conversion from
MCI to AD
With the aim to better investigate the blood DC decline
during AD progression, we have taken into consider-
ation a subgroup of MCI converters and compared their
peripheral blood DC frequency between before and after
conversion. The clinical characteristics of the MCI
groups of subjects at baseline are summarized in Table 2.
No main differences have been observed between the
MCI converter subgroup and the whole MCI group as
for age, education level, and gender distribution. As re-
ported in Fig. 3a, most of the donors (9/11) showed a
Table 1 Demographic and clinical characteristics of HC, MCI, and AD subjects
HC MCI AD AD w/o AChEI AD AChEI
n 73 65 106 40 66
Gender (female, %) 57.2 57.0 51.9 55.0 50.0
Age (years) 71.5 ± 0.5 71.2 ± 0.7 72.1 ± 0.6 72.3 ± 1.0 71.9 ± 0.8
Education (years) 11.3 ± 0.5 9.0 ± 0.5* 8.5 ± 0.5** 9.0 ± 0.7* 8.1 ± 0.7**
MMSE 28.6 ± 0.1 27.0 ± 0.2** 20.9 ± 0.4** 22.0 ± 0.6** 20.0 ± 0.6**
ADL 5.9 ± 0.3 6.1 ± 0.05 8.5 ± 0.3** 8.0 ± 0.3** 8.9 ± 0.5**
IADL 6.7 ± 0.2 7.2 ± 0.2 13.8 ± 0.6** 12.9 ± 0.8** 14.6 ± 0.8**
NPI dep. (F × S) 1.3 ± 0.2 2.1 ± 0.2* 3.0 ± 0.2** 3.4 ± 0.4** 2.7 ± 0.3**
Data are expressed as mean ± SEM; *p < 0.005 and **p < 0.0005 vs HC
MMSE mini-mental status examination, ADL activities of daily living, IADL instrumental activities of daily living, NPI dep. (F × S) neuropsychiatric
inventory–depression (frequency × severity)
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decrease in mDC levels following AD conversion. Over-
all, the mean percentage of mDCs was significantly
decreased in MCI converter (0.25 ± 0.020) only after
their conversion to AD (0.17 ± 0.021, p = 0.002). Further-
more, the levels of mDCs were similar comparing the
total group of MCI, the subgroup of MCI which is not
converted to AD and the subgroup of MCI that converts
to AD analyzed before conversion (Table 2). No differ-
ences in pDC values were identified in MCI converters
between before and after conversion (Fig. 3b).
Relationship between mDC levels and depression in AD
patients
Correlation analysis was performed in order to assess
possible associations between frequencies of blood DCs
and functional assessment of AD patients, such as cogni-
tive deterioration and behavioral and psychological
symptoms. A significant inverse correlation was found
between mDC levels and depression symptoms (n = 91,
p = 0.01, rho = −0.25). As shown in Fig. 4, blood DC
levels were lower in patients with higher NPI scores, as
regards in particular the frequency × severity of depres-
sive symptoms. Interestingly, this correlation was signifi-
cant in the case of mDC subset (Fig. 4a), while not for
pDCs (Fig. 4b). No significant correlations were identi-
fied in AD patients between blood DC subsets and the
other 11 NPI subscales, ADL, IADL, or MMSE scores
(data not shown). Finally, the treatment of AD patients
with antidepressants did not appear to influence the
above-described correlation. In fact, similar to the whole
group of AD patients, a significant inverse correlation
between mDC levels and NPI score of depression was
observed in AD patients who did not undergo to any
depression medication not treated with antidepressant
drugs (data not shown). No associations between blood
DC subsets and symptom severity were identified in
MCI patients, both total group and MCI subgroups
(data not shown).
Blood mDC reduction is abated in AD patients treated
with AChEI
Since AD patients are commonly treated with cholin-
esterase inhibitors, which exert symptomatic effects and
some delaying of disease progression, we ought to evalu-
ate a potential interference of AChEI treatment on blood
DCs frequency. Thus, we split our AD cohort into two
subgroups, including AChEI-untreated and AChEI-
treated patients and their characteristics are summarized
in Table 1. As shown in Fig. 5a, the mDC mean percent-
age in untreated AD patients (AD w/o AChEI; 0.16 ±
0.014) was significantly decreased as compared to HC
(0.24 ± 0.012, p < 0.0001), as well as AD patients receiv-
ing AChEI therapy (AD AChEI; 0.22 ± 0.011). At vari-
ance, the mDC levels in the AChEI-treated subgroup of
AD were only slightly lower than those observed in HC,
without any significant difference between them, sug-
gesting that the anti-cholinesterase therapy may mitigate
the blood mDC reduction observed in AD patients. No
differences among the two groups of AChEI-untreated
and AChEI-treated patients and HC were observed re-
garding the levels of blood pDCs (Fig. 5b).
Discussion
In recent years, DCs have emerged as a promising re-
search area to investigate CNS diseases’ pathophysiology
and although a number of studies showed that DCs play
critical roles in CNS inflammation, particularly during
stroke or multiple sclerosis (MS) [20, 32], less evidence
points to their potential role in neurodegenerative dis-
eases. In this context, our data support the hypothesis
that blood DCs are altered in AD patients.
Our main finding is that AD patients have decreased
levels of the myeloid subset of blood DCs, as compared
to matched HC. DC reduction is probably a general
phenomenon in several full-blown diseases, since it has
been featured in autoimmune diseases [33–35], infec-
tions [36], cancer [37], and CNS disturbances [19–21].
The blood DC reduction can be due to alterations in DC
viability, DC mobilization, or their impaired differenti-
ation from progenitors. Hence, the fate of DCs missing
from the bloodstream is not always the same. In some
cases, blood DCs specifically migrate from the blood to
the diseased tissue. This situation was described in
stroke or MS, where DCs have been found in the brain
[20, 38], or in coronary artery disease, where DCs have
been identified in atherosclerotic plaques [39]. On the
contrary, DCs may die following infection, as in malaria
[40], HIV infection [41], or severe sepsis [42], where
infected DCs have been shown to undergo apoptosis.
This latter circumstance seems unlikely to happen in
Table 2 Demographic and clinical characteristics of MCI subjects
at baseline
MCI total group MCI converters MCI no-converters




Age (years) 70.1 ± 0.7 72.4 ± 2.3 70.9 ± 0.7
Education (years) 8.8 ± 0.5 8.6 ± 1.2 9.1 ± 0.6
MMSE 27.1 ± 0.2 26.9 ± 0.7 26.9 ± 0.2
ADL 6.1 ± 0.04 6.6 ± 0.4 6.1 ± 0.04
IADL 6.9 ± 0.2 8.0 ± 0.8 7.1 ± 0.2
NPI dep. (F × S) 1.9 ± 0.2 0.7 ± 0.3* 2.4 ± 0.3
pDCs (%) 0.073 ± 0.005 0.077 ± 0.02 0.072 ± 0.005
mDCs (%) 0.26 ± 0.011 0.25 ± 0.02 0.26 ± 0.012
Data are expressed as mean ± SEM; *p < 0.05 vs MCI total group and MCI
no converters
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AD patients, where we did not observe an abnormal
number of apoptotic DC in the peripheral blood (data
not shown). Conversely, as previously demonstrated in
stroke and MS, we speculate that in AD, a significant
percentage of blood mDCs move from peripheral blood
probably reaching the brain of patients, maybe at chor-
oid plexus or meninges level, where DCs could sample
cerebrospinal fluid content. To this regard, a part of Aβ
peptide efflux has been described to occur in AD exactly
from these CNS elimination routes [43]. After DCs have
reached these privileged positions, and sampled brain
antigens, they may respond to neuroinflammation sig-
nals and react to neurodegeneration [44]. Importantly,
the recent and accurate description of a CNS lymphatic
Fig. 1 Representative dot plots showing the gating strategy to identify mDCs and pDCs by flow cytometry. Whole peripheral leukocytes were
selected from live cells based on forward scatter and side scatter characteristics (a, gate R1). Blood DCs were then selected within R1 positive
cells as negative for lineage markers (lin-1) (b, gate R2). Finally, blood DCs were identified as mDC (d, HLA-DR+/CD11c+/CD123−, gate R3) or pDC
(f, HLA-DR+/CD11c−/CD123+, gate R4) in comparison to respective isotype control monoclonal antibodies (c, e)
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system connected to deep cervical lymph nodes, which
are able to drain cerebrospinal fluid and carry immune
cells such as CD11c+ [45], leads to more thorough
investigation of the leukocyte presence in CNS immune
responses in neurodegeneration and supports our hy-
pothesis about blood-derived DC involvement in AD
brain pathology.
Notably, we observed a specific reduction of myeloid
DCs, while pDC subset appears mostly unchanged. This
is in line with recent GWAS studies where the involve-
ment of numerous immune-related genes as risk factors
for AD was highlighted. Among these genes, there are
CD33 and TREM2 notoriously associated with myeloid
cell function. These studies strongly suggest that mye-
loid compartment of the immune system is a crucial
component of susceptibility to AD [46]. Although it is
still unclear to what extent peripheral myeloid cells en-
graft in the AD brain, it has been observed that CD33
expression levels are increased in CNS, but appeared de-
creased in peripheral mononuclear cells of AD patients
[47], suggesting that central and peripheral myeloid cell
frequency may be linked processes during the disease.
Furthermore, the specific implication of the mDC
subset in AD is consistent with a more pronounced
pro-inflammatory feature of this subpopulation as com-
pared to pDCs [48], also converging with our previous
in vitro studies, which showed that monocyte-derived
DCs acquire a pro-inflammatory profile in AD condi-
tions [3, 22, 23].
Differently from AD, we recently reported that in PD
patients, there is a reduction of blood DCs both in
mDCs and pDCs [21]. This last observation suggests
that mDC decrease in the blood may be a common
phenomenon in patients with neurodegenerative dis-
eases, though DC subsets may be endowed with differ-
ent functions in neuroinflammatory pathway linked to
neurodegeneration evolution, depending on the type of
specific neurological disturbance.
In the present study, we propose that blood mDC de-


































Fig. 2 Peripheral blood mDCs decline in AD patients. The distribution of percentage values of mDCs (a) and pDCs (b) present in the blood of HC
(n = 73), MCI (n = 65), and AD (n = 106) subjects is reported in the respective scatter dot plot, as indicated. The black bars indicate the mean. *p =





























Fig. 3 Peripheral blood mDCs decline with AD conversion. “Before and after” graph showing levels of mDCs (a) and pDCs (b) in a subgroup of
11 MCI converting to AD during a follow-up of 2 years. *p = 0.002 (Wilcoxon matched paired test)
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the immune cell perturbation becomes evident in MCI
subjects only after their conversion to AD while it is not
evident at MCI level. Further, the blood mDC decrease is
associated with severity and frequency of the depressive
episodes and comes out mitigated in patients treated
with the AChEI drugs used to slow down disease
progression.
In fact, regarding the MCI subjects, namely individ-
uals at increased risk to develop dementia, we ob-
served that mDC levels were not different from those
observed in control donors. This was true not only
for the whole group of MCI but also for MCI con-
verters, the retrospectively identified subgroup of MCI
patients who have subsequently converted to AD,
hence in the earliest phase of AD. This indicates that
blood mDC depletion specifically occurs only after
the onset of AD symptoms suggesting that DCs may
be involved in AD progression, but not in the earlier
phases of dementia.
We also found low mDC levels associated with in-
creased depressive severity suggesting that depletion of
mDC subset in AD may be a functional feature of
neuroinflammation-dependent neurodegenerative symp-
toms. The possibility that DC alteration may be linked
to depressive symptoms is not very surprising, since
depression and dementia share many common patho-
physiological features with chronic inflammation, activa-
tion of the hypothalamic–pituitary–adrenal axis and
deficit of neurotrophin signalling [49].
Finally, we observed that reduction of blood mDCs
did not occur in AD patients treated with AChEI. These
drugs, recommended as first-line treatment option for





























Fig. 4 Relationship between depression symptoms scores and levels of mDCs in AD patients. The correlation between depression symptoms
scores (NPI) and percentage values of either mDCs (a) or pDCs (b) present in the blood of AD patients (n = 106) is reported in the respective





















































Fig. 5 Treatment with AChEI modulates the level of mDCs in AD patients. The distribution of percentage values of mDCs (a) and pDCs (b) present in
the blood of HC (n = 73), AD without AChEI treatment (n = 40), and AD treated with AChEI (n = 66) is reported in the respective scatter dot plot, as
indicated. The black bars indicate the mean. *p < 0.0001
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patients with mild to moderate AD, exert symptomatic
effects and delay the natural course of the disease, sup-
porting the hypothesis of an association between blood
mDC perturbation and AD progression. Interestingly,
AChEI treatment has been also reported to have benefi-
cial effects on behavioural disturbances, including de-
pression [50], further strengthening the suggested link
between mDC frequency, AD progression, and depres-
sive symptoms. In addition, AChEI, which are commonly
used to compensate for acetylcholine depletion in AD
brains, other than enhancing cholinergic transmission,
may also exert anti-inflammatory activity on both neuro-
inflammation [51] and systemic inflammation [52]. Since
a recent study showed that acetylcholine modulates
functions of DCs cultured in vitro through an autocrine/
paracrine loop [53], further studies are highly recom-
mended in order to identify the anti-inflammatory
mechanisms of AChEI, DC-mediated.
Limits of the study
To our knowledge, this is the first study that analyzes the
main subpopulations of circulating DCs in AD patients.
Below are some points listed that should be investigated
further. (i) We hypothesize that the main remark of this
study, namely the reduction of mDCs from blood of AD
patients, is associated with the recruitment of these cells in
the brain. However, we did not investigate directly the fate
of DCs, but we supposed their recruitment in the brain,
taking in consideration previously reported studies [20, 38].
Although clarifying the fate of myeloid DCs would allow
to describe the phenotypic and functional features of
these cells missing from the blood of AD patients, it is
hindered by the difficulty to monitor the patients’ brain
for infiltrating myeloid cell subpopulations. (ii) We per-
formed a cell staining strategy that allowed us to identify
two different subpopulations of circulating DCs (lin-1-/
HLA-DR++/CD11c+/CD123-, myeloid DCs and lin-1-/
HLA-DR++/CD11c-/CD123+, plasmacytoid DCs) but a
more detailed DC characterization by BDCA’s analysis
[54] may prove useful to identify further distinctive DC
subsets involved in AD. (iii) Finally, this study did not
take into account the analysis of AD biomarkers and neu-
roimaging of brain inflammation, whose possible correl-
ation with blood DC levels might add to our findings.
The above limits are open questions which deserve to be
clarified in future studies.
Blood DCs as potential biomarkers
In recent years, it has been shown that DCs may be a
source of molecular marker for many diseases. For ex-
ample, it has been shown that in lung tumors, mature
DCs represent a specific marker for tumor-associated
local lymph node-like structures [55] and, in some forms
of leukemia, a specific subpopulation of BAD-LAMP+
pDCs identifies transformed pDCs [56]. In diabetes, it
has been suggested that pDCs could predict Th1-
mediated type 1 disease [57] while, in systemic lupus
erythematosus (SLE), there is strong genetic evidence
that pDCs are critically involved in pathogenesis and
autoantibody production [58]. The concept of im-
mune processes as AD biomarker resource in neuro-
degenerative diseases is quite at the beginning. In
particular, it has been shown that AD-derived mono-
cytes exhibit an impaired differentiation into macro-
phages in vitro and also a limited phagocytic ability with
a surface uptake of Aβ undergoing apoptosis after Aβ ex-
posure [5]. Interestingly, a decreased abundance of mono-
cytes was described in MCI compared with AD patients,
suggesting a transient decline in the number of monocytes
in the early stages of the disease [59]. More recently, lower
levels of absolute percent of CD14 cells in early AD pa-
tients and an altered expression of HLA-DR, CD16, and
CCR2 were found [60]. All studies reported above, includ-
ing our findings, suggest that myeloid-derived cells, start-
ing from monocytes to DCs, are impaired in AD, leading
to ask what is the real contribution of these cells to the de-
velopment of AD and whether they may be considered for
further development of clinically relevant tools.
Conclusions
We identified blood mDCs as a cell population of high
potential interest in AD progression and treatment, even
though future longitudinal studies accompanied by
evaluation of biomarkers, like those searching for Aβ
and tau proteins in cerebrospinal fluid, and specialized
PET and MRI scans may be useful to better understand
the meaning of mDC decline in AD clinical course.
In conclusion, this study provides the first evidence
that blood DCs, specifically those of myeloid origin, are
dysregulated in the blood of AD patients, fostering the
concept that blood immune cells may play a key role in
inflammatory-mediated progression of AD.
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